MedTrace Logo

ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

NCT06194799 · Status: ENROLLING_BY_INVITATION · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 752

Last updated 2026-05-04

No results posted yet for this study

Summary

This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.

Conditions

  • Alzheimer's Disease Psychosis

Interventions

DRUG

ACP-204

ACP-204 30 mg given once daily, as capsule OR ACP-204 60 mg given once daily, as capsule

Sponsors & Collaborators

  • ACADIA Pharmaceuticals Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-23
Primary Completion
2029-04-30
Completion
2029-05-31
FDA Drug
Yes

Countries

  • United States
  • Brazil
  • Bulgaria
  • Chile
  • Czechia
  • France
  • Italy
  • Mexico
  • Serbia
  • South Korea
  • Spain
  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06194799 on ClinicalTrials.gov